Session Information

WCLC 2021

2021 World Conference on Lung Cancer

Conference Program for 2021 the World Conference on Lung Cancer
Presentation Date(s):
- September 8 - 14, 2021
- Total Presentations: 1107
All times listed are in Mountain Time MDT (UTC-6:00)

PL - Plenary
ES - Education Session
OA - Oral Session
MA - Mini Oral Session
FP - Featured Posters
P - Posters
WS - Workshops
IS - Industry Symposium
MTE - Meet the Expert
BEDG - Brain Exchange Discussion Groups
Register to Attend WCLC Login to WCLC2021 Switch to Virtual Meeting

All Days Wednesday
September 8 Wed
Sep 8 Thursday
September 9 Thu
Sep 9 Friday
September 10 Fri
Sep 10 Saturday
September 11 Sat
Sep 11 Sunday
September 12 Sun
Sep 12 Monday
September 13 Mon
Sep 13 Tuesday
September 14 Tue
Sep 14

Filter Results:

Show Only CME Accredited Sessions

37307

+
FP09 - Novel Therapeutics and Targeted Therapies
- 00:00 - 00:00
- 9/08/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters (Featured)
- Track: Novel Therapeutics and Targeted Therapies
- 37309
  
  +
  
  FP09.01 - Mobocertinib in Platinum-Pretreated EGFR Exon 20 Insertion+ Metastatic NSCLC Patients With/Without Prior Anti-PD(L)-1 Therapy
  
  00:00 - 00:00 | Presenter: Pasi A. Janne
  Abstract
  
  Loading...
- 37310
  
  +
  
  FP09.02 - Mobocertinib (TAK-788) in EGFR Exon 20 Insertion+ Metastatic NSCLC: Patient-Reported Outcomes From EXCLAIM Extension Cohort
  
  00:00 - 00:00 | Presenter: Maria Rosario García Campelo
  Abstract
  
  Loading...
37621

+
P15 - Immunotherapy (Phase II/III Trials) - Early Stage NSCLC
- 00:00 - 00:00
- 9/08/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Immunotherapy (Phase II/III Trials)
- 37623
  
  +
  
  P15.02 - Toripalimab and Platinum-Doublet Chemotherapy as Neoadjuvant Therapy for Potentially Resectable Non-Small Cell Lung Cancer
  
  00:00 - 00:00 | Presenter: Yongchang Zhang
  Abstract
  
  Loading...
37642

+
P19 - Immunotherapy (Phase II/III Trials) - Previously Treated NSCLC
- 00:00 - 00:00
- 9/08/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Immunotherapy (Phase II/III Trials)
- 37643
  
  +
  
  P19.01 - RATIONALE-303 Phase 3 Tislelizumab vs Docetaxel in Previously Treated Advanced NSCLC: China Subgroup Analysis
  
  00:00 - 00:00 | Presenter: Yun Fan
  Abstract
  
  Loading...
38057

+
P51 - Novel Therapeutics and Targeted Therapies - EGFR Resistance
- 00:00 - 00:00
- 9/08/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Novel Therapeutics and Targeted Therapies
- 38060
  
  +
  
  P51.03 - Oritinib (SH-1028), a Third-generation EGFR-TKI in Advanced NSCLC Patients with Positive EGFR T790M: Results of a Single-arm Phase Ib Trial
  
  00:00 - 00:00 | Presenter: Caicun Zhou
  Abstract
  
  Loading...
37842

+
P60 - Predictive Tumor Based Assays/ Biomarkers/ Pathology - Other Biomarkers
- 00:00 - 00:00
- 9/08/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Predictive Tumor Based Assays/ Biomarkers/ Pathology
- 37845
  
  +
  
  P60.03 - Transcriptome and Genome Profiles of Metastatic Lung Cancers Highlighted Predictive Power of Infection-Related Model in Metastasis
  
  00:00 - 00:00 | Presenter: Peixin Chen
  Abstract
  
  Loading...
37763

+
P66 - Small Cell Lung Cancer/ NET - Pre-Clinical
- 00:00 - 00:00
- 9/08/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Small Cell Lung Cancer/ NET
- 37769
  
  +
  
  P66.06 - GPNMB Associates With Inferior Prognosis in SCLC Patients Through Promoting Tumor Cell Metastasis
  
  00:00 - 00:00 | Presenter: qian liu
  Abstract
  
  Loading...
37987

+
PL02 - Plenary 2: Presidential Symposium (Japanese, Mandarin, Spanish Translation Available)
- 06:30 - 08:00
- 9/09/2021
- Location: Program Auditorium
- IASLC CME Accredited
- Type: Plenary
- Track: N.A.
- Moderators:David Harpole, Tetsuya Mitsudomi
- 38263
  
  +
  
  PL02.05 - IMpower010: Characterization of Stage IB-IIIA NSCLC Patients by Type and Extent of Therapy Prior to Adjuvant Atezolizumab
  
  07:04 - 07:14 | Presenter: Nasser Altorki
  Abstract
  
  Loading...
38001

+
PL02A - Plenary 2: Presidential Symposium (Rebroadcast) (Japanese, Mandarin, Spanish Translation Available)
- 14:30 - 16:00
- 9/09/2021
- Location: Program Auditorium
- IASLC CME Accredited
- Type: Plenary
- Track: N.A.
- Moderators:David Harpole, Tetsuya Mitsudomi
- 38290
  
  +
  
  PL02A.05 - IMpower010: Characterization of Stage IB-IIIA NSCLC Patients by Type and Extent of Therapy Prior to Adjuvant Atezolizumab
  
  15:04 - 15:14 | Presenter: Nasser Altorki
  Abstract
  
  Loading...
36918

+
WS06 - Joint IASLC - CAALC - CSCO Workshop: Looking Toward the Future: Recognizing and Curing Lung Cancer
- 22:15 - 23:45
- 9/11/2021
- Location: Program Auditorium
- Not for CME Credit
- Type: Workshop
- Track: N.A.
- Moderators:Caicun Zhou, ChunXue Bai
- 36919
  
  +
  
  WS06.01 - Introduction
  
  22:15 - 22:17 | Presenter: ChunXue Bai, Caicun Zhou
  Abstract
  
  No abstract available for this presentation
- 36920
  
  +
  
  WS06.02 - RWS on PNapp MIOT Study on Pulmonary Nodule and Updates of 9th Edition of NSCLC TNM Staging Project in China
  
  22:17 - 22:29 | Presenter: Dawei Yang
  Abstract
  
  No abstract available for this presentation
- 36921
  
  +
  
  WS06.03 - Neoadjuvant/Adjuvant Target Therapy for Curing Driver Genes Positive Resectable NSCLC
  
  22:29 - 22:41 | Presenter: Wen-zhao Zhong
  Abstract
  
  No abstract available for this presentation
- 36922
  
  +
  
  WS06.04 - Neoadjuvant/Adjuvant Immunotherapy for Curing Non-driver Genes Resectable NSCLC
  
  22:41 - 22:53 | Presenter: Heather Wakelee
  Abstract
  
  No abstract available for this presentation
- 38293
  
  +
  
  WS06.05 - RATIONALE-307: Updated Biomarker Analysis of Phase 3 Study of Tislelizumab Plus Chemo vs Chemo Alone For 1L Advanced Sq-NSCLC
  
  22:53 - 23:03 | Presenter: Jie Wang
  Abstract
  
  Loading...
- 38121
  
  +
  
  WS06.06 - Drug Holiday Based on Minimal Residual Disease Status After Local Therapy Following EGFR-TKI Treatment for Patients With Advanced NSCLC
  
  23:03 - 23:13 | Presenter: Song Dong
  Abstract
  
  Loading...
- 38120
  
  +
  
  WS06.07 - Lorlatinib for Previously Treated ALK-Positive Advanced NSCLC: Primary Efficacy and Safety Data from a Phase 2 Study in China
  
  23:13 - 23:23 | Presenter: Shun Lu
  Abstract
  
  Loading...
- 38114
  
  +
  
  WS06.08 - Discussant
  
  23:23 - 23:31 | Presenter: Mingfang Zhao
  Abstract
  
  No abstract available for this presentation
- 38115
  
  +
  
  WS06.09 - Live Panel Discussion with Speakers and Chairs
  
  23:31 - 23:45 | Presenter: Yi-Long Wu, Tony Mok
  Abstract
  
  No abstract available for this presentation
37169

+
MA13 - Building on the Past: What Will Be the Next Immunotherapy Combination?
- 17:30 - 18:30
- 9/13/2021
- Location: Program Auditorium
- IASLC CME Accredited
- Type: Mini Oral
- Track: Immunotherapy (Phase II/III Trials)
- 37170
  
  +
  
  MA13.01 - Camrelizumab Plus Apatinib in Treatment-Naive Patients With Advanced Non-Squamous NSCLC: A Multicenter, Open-Label, Single-Arm, Phase 2 Trial
  
  17:30 - 17:35 | Presenter: Shengxiang (Harry) Ren
  Abstract
  
  Loading...
- 37608
  
  +
  
  MA13.07 - GEMSTONE-302: A Phase 3 Study of Platinum-Based Chemotherapy with Placebo or Sugemalimab, a PD-L1 mAb, for metastatic NSCLC
  
  18:05 - 18:10 | Presenter: Caicun Zhou
  Abstract
  
  Loading...
- 37628
  
  +
  
  MA13.08 - CHOICE-01: A Phase 3 Study of Toripalimab Versus Placebo in Combination With First-Line Chemotherapy for Advanced NSCLC
  
  18:10 - 18:15 | Presenter: Jie Wang
  Abstract
  
  Loading...

Session Information

WCLC 2021

2021 World Conference on Lung Cancer

+

FP09 - Novel Therapeutics and Targeted Therapies

+

FP09.01 - Mobocertinib in Platinum-Pretreated EGFR Exon 20 Insertion+ Metastatic NSCLC Patients With/Without Prior Anti-PD(L)-1 Therapy

+

FP09.02 - Mobocertinib (TAK-788) in EGFR Exon 20 Insertion+ Metastatic NSCLC: Patient-Reported Outcomes From EXCLAIM Extension Cohort

+

P15 - Immunotherapy (Phase II/III Trials) - Early Stage NSCLC

+

P15.02 - Toripalimab and Platinum-Doublet Chemotherapy as Neoadjuvant Therapy for Potentially Resectable Non-Small Cell Lung Cancer

+

P19 - Immunotherapy (Phase II/III Trials) - Previously Treated NSCLC

+

P19.01 - RATIONALE-303 Phase 3 Tislelizumab vs Docetaxel in Previously Treated Advanced NSCLC: China Subgroup Analysis

+

P51 - Novel Therapeutics and Targeted Therapies - EGFR Resistance

+

P51.03 - Oritinib (SH-1028), a Third-generation EGFR-TKI in Advanced NSCLC Patients with Positive EGFR T790M: Results of a Single-arm Phase Ib Trial

+

P60 - Predictive Tumor Based Assays/ Biomarkers/ Pathology - Other Biomarkers

+

P60.03 - Transcriptome and Genome Profiles of Metastatic Lung Cancers Highlighted Predictive Power of Infection-Related Model in Metastasis

+

P66 - Small Cell Lung Cancer/ NET - Pre-Clinical

+

P66.06 - GPNMB Associates With Inferior Prognosis in SCLC Patients Through Promoting Tumor Cell Metastasis

+

PL02 - Plenary 2: Presidential Symposium (Japanese, Mandarin, Spanish Translation Available)

+

PL02.05 - IMpower010: Characterization of Stage IB-IIIA NSCLC Patients by Type and Extent of Therapy Prior to Adjuvant Atezolizumab

+

PL02A - Plenary 2: Presidential Symposium (Rebroadcast) (Japanese, Mandarin, Spanish Translation Available)

+

PL02A.05 - IMpower010: Characterization of Stage IB-IIIA NSCLC Patients by Type and Extent of Therapy Prior to Adjuvant Atezolizumab

+

WS06 - Joint IASLC - CAALC - CSCO Workshop: Looking Toward the Future: Recognizing and Curing Lung Cancer

+

WS06.01 - Introduction

+

WS06.02 - RWS on PNapp MIOT Study on Pulmonary Nodule and Updates of 9th Edition of NSCLC TNM Staging Project in China

+

WS06.03 - Neoadjuvant/Adjuvant Target Therapy for Curing Driver Genes Positive Resectable NSCLC

+

WS06.04 - Neoadjuvant/Adjuvant Immunotherapy for Curing Non-driver Genes Resectable NSCLC

+

WS06.05 - RATIONALE-307: Updated Biomarker Analysis of Phase 3 Study of Tislelizumab Plus Chemo vs Chemo Alone For 1L Advanced Sq-NSCLC

+

WS06.06 - Drug Holiday Based on Minimal Residual Disease Status After Local Therapy Following EGFR-TKI Treatment for Patients With Advanced NSCLC

+

WS06.07 - Lorlatinib for Previously Treated ALK-Positive Advanced NSCLC: Primary Efficacy and Safety Data from a Phase 2 Study in China

+

WS06.08 - Discussant

+

WS06.09 - Live Panel Discussion with Speakers and Chairs

+

MA13 - Building on the Past: What Will Be the Next Immunotherapy Combination?

+

MA13.01 - Camrelizumab Plus Apatinib in Treatment-Naive Patients With Advanced Non-Squamous NSCLC: A Multicenter, Open-Label, Single-Arm, Phase 2 Trial

+

MA13.07 - GEMSTONE-302: A Phase 3 Study of Platinum-Based Chemotherapy with Placebo or Sugemalimab, a PD-L1 mAb, for metastatic NSCLC

+

MA13.08 - CHOICE-01: A Phase 3 Study of Toripalimab Versus Placebo in Combination With First-Line Chemotherapy for Advanced NSCLC

Stay Connected